Understanding health equity in Alzheimer's treatment for underserved populations
Health Equity in Alzheimer’s Treatment (HEAT)
This study is looking at how to make anti-amyloid medications more effective and affordable for Black and low-income people in Flint, Michigan, who are at higher risk for Alzheimer's Disease, by talking to community members about their experiences and challenges with diagnosis and treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10975428 on NIH RePORTER |
What this research studies
This research investigates how anti-amyloid medications can be effectively and affordably used in Black and low-income populations who are at higher risk for Alzheimer's Disease and related dementias. The project will engage community stakeholders in Flint, Michigan, to gather insights through interviews and surveys about the challenges these populations face regarding diagnosis, treatment, and costs. By focusing on real-world effectiveness and cost-effectiveness, the research aims to identify barriers and preferences that affect treatment outcomes for these communities.
Who could benefit from this research
Good fit: Ideal candidates for this research include Black individuals and those from low-income backgrounds who are experiencing mild cognitive impairment or Alzheimer's Disease.
Not a fit: Patients who do not belong to Black or low-income populations may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access and tailored treatment strategies for Alzheimer's patients in underserved populations.
How similar studies have performed: While there has been research on Alzheimer's treatment, this specific focus on health equity in underserved populations is relatively novel and untested.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Callaghan, Brian Christopher — University of Michigan at Ann Arbor
- Study coordinator: Callaghan, Brian Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.